Holen Sie sich die Stockscreener-App
41.55
2.01%
0.82
Handel nachbörslich:
42.05
0.50
+1.20%
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2025 Earnings Call Transcript - Insider Monkey
Hatteras Venture Partners Raises Over $200 Million in Capital Across Two Healthcare-Focused Funds - GlobeNewswire Inc.
Kymera Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Kymera Therapeutics’ Earnings Call: Optimism and Strategic Progress - TipRanks
Kymera Therapeutics: Promising Developments in STAT6 Degrader KT-621 Drive Buy Rating - TipRanks
Kymera extends cash runway to 2H 2028 as immunology pipeline advances and collaborations boost funding - MSN
Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ... - Yahoo Finance
Kymera Therapeutics Reports Q2 2025 Progress and Partnerships - TipRanks
Kymera Therapeutics shares fall 1.14% after-hours after reporting a widened Q2 loss and falling collaboration revenue. - AInvest
Kymera Therapeutics Q2 2025: Unpacking Contradictions in Clinical Expectations, Safety Monitoring, and Dosing Strategies - AInvest
Kymera Therapeutics: Strategic Catalysts and Monetization Potential in a High-Stakes Biotech Landscape - AInvest
Kymera Extends Cash Runway, Boosts Funding through Immunology Pipeline Advancements and Collaborations. - AInvest
Kymera Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Transcript : Kymera Therapeutics, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Earnings call transcript: Kymera Therapeutics Q2 2025 results miss forecasts By Investing.com - Investing.com South Africa
Kymera Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kymera Q2 2025 slides: Strong pipeline advances despite revenue decline By Investing.com - Investing.com Australia
Kymera Q2 2025 slides: Strong pipeline advances despite revenue decline - Investing.com
Kymera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Kymera Revenue Drops 55 Percent in Q2 - The Globe and Mail
Kymera’s Losses Widen But Wall Street Stays Optimistic - Finimize
Kymera Therapeutics, Inc. SEC 10-Q Report - TradingView
Kymera Therapeutics' Q2 2025 Earnings Miss: A Test of Resilience in the TPD Space? - AInvest
Kymera Therapeutics Q2 Loss Widens, Collaboration Revenue Falls - MarketScreener
Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q2 Revenue $11.5M, vs. FactSet Est of $22.2M - MarketScreener
Earnings Flash (KYMR) Kymera Posts Q2 Loss $0.95 a Share, vs. FactSet Est of $0.89 Loss - MarketScreener
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update - The Manila Times
Kymera Therapeutics Q2 revenue misses expectations, net loss widens - TradingView
Kymera Reports Phase 1 Success, Secures $750M Gilead Partnership with $1B Cash Position | KYMR Stock News - Stock Titan
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit - MSN
Kymera Therapeutics Earnings Preview: What to Expect - AInvest
Kymera Therapeutics KYMR Q2 2025 Earnings Preview Upside Potential Driven by Strategic Partnerships - AInvest
Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q2 2025 Result - Yahoo Finance
Kymera Therapeutics Becomes Oversold (KYMR) - Nasdaq
Earnings Preview: KYMR to Report Financial Results Pre-market on August 11 - 富途牛牛
Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025 - The Manila Times
Kymera Therapeutics reports Q2 2025 results, plans call on August 11. - AInvest
Clinical-Stage Biotech Kymera Therapeutics Sets Q2 Earnings Date: Key Updates Expected on Immunology Pipeline - Stock Titan
Is Kymera Therapeutics Inc. a growth stock or a value stockFree Investment Community - Jammu Links News
How does Kymera Therapeutics Inc. generate profit in a changing economyTransform your portfolio with high-yield stocks - Jammu Links News
What catalysts could drive Kymera Therapeutics Inc. stock higher in 2025Get expert analysis on top stock picks - Jammu Links News
What makes Kymera Therapeutics Inc. stock price move sharplyAchieve consistent profits with proven methods - Jammu Links News
Should I hold or sell Kymera Therapeutics Inc. stock in 2025Dynamic portfolio growth - Jammu Links News
How many analysts rate Kymera Therapeutics Inc. as a “Buy”Stay ahead with daily market updates - Jammu Links News
Why is Kymera Therapeutics Inc. stock attracting strong analyst attentionUnlock powerful trading tools for investors - Jammu Links News
What is Kymera Therapeutics Inc. company’s growth strategyExplosive earning power - Jammu Links News
What analysts say about Kymera Therapeutics Inc. stockCapitalize on emerging trends for profits - Jammu Links News
How strong is Kymera Therapeutics Inc. company’s balance sheetSwing Trade Review With Proven Results - Jammu Links News
Kymera Therapeutics: A Biotech Company with a Promising Future - AInvest
Is it the right time to buy Kymera Therapeutics Inc. stockBreakout Stocks Ideas For 2025 - Jammu Links News
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer - MSN
Kymera Therapeutics Inc. Chart Enters High Volatility ZoneSecure Return Focused Investment Plan Released - metal.it
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Published on: 2025-07-29 17:18:26 - metal.it
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):